BNET Industries

Last Fiscal Year Sales:$133.0K
  • Public
  • US
Dow Jones Description

We are an early-stage biotechnology company focused on the acquisition and development of novel technologies and products to address significant, unmet medical needs. Our strategy is to in-license and to develop products through human proof-of-concept studies (Phase I and II clinical trials of the U.S. Food and Drug Administration's regulatory process) prior to partnering with major pharmaceutical, biotechnology or healthcare product firms for advanced clinical development and commercialization. Our most advanced product, which we refer to as replacement therapy, is a one-time topical treatment to prevent tooth decay. The FDA has approved our Investigational New Drug application ("IND") for replacement therapy and we plan to begin Phase I trials in 2005. Since inception, we have funded a significant portion of our operations from the public and private sales of our securities. We have generated no significant revenues from operations during the last two years. All of our revenues have been from a sponsored research agreement and Small Business Innovation Research ("SBIR") grants which have expired. We have not generated revenues from sales of products.

President & CEO
Bruce Stein Stanley
Number of Employees 9
Contact Information

12085 Research Dr

Alachua, Florida 32615

oragenics.com

(386) 418-4018

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • StockProfiler.US: Stock Profiler.US: Stock Watch: ORNI, PFAP, NHLD, SIAF

    10/12/09 - Product Announcement - View Story

  • Oragenics Launches Teddys Pride Oral Care for Dogs and Cats

    10/12/09 - Product Announcement - View Story

  • Oragenics Announces $5,000,000 in New Financing, and Changes in Its Board of Directors and Management

    8/29/09 - New Investment - View Story

  • Oragenics Secures New Financing and Makes Changes to Its Board and Management

    7/07/09 - Joint Venture / Alliance - View Story

News & Analysis

oragenics inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Bruce Stein Stanley President & CEO
David B Hirsch Acting President and Chief Executive Officer
Robert Zahradnik President & CEO
Ronald P. Evens CEO & President
Stanley B Stein Interim President and Chief Executive Officer and Director
Dr Jeffrey Hillman President
Brian John Bohunicky Chief Financial Officer
Brian Mouatt Th Chief Dental Officer for England
Dorothy J. Delfino Chief Financial Officer
George T. Hawes Oragenics, Inc. Director
Hari Parkash Director for Its Center Dental Studies and Research
Howard K Kuramitsu Professor at the State University of New York at Buffalo
Paul A Hassie
Per-Erik J Saris Professor
Kevin H Sills Director

Board of Directors

Name (plus bio) Position
David J. Gury Chairman and Director
Christine L. Koski Board of Directors
Derek G. Hennecke Board of Directors
Lane Markham Board of Directors
Marc K Siegel Board of Directors
Richard T Welch Board of Directors

Organization Position Status
Oragenics, Inc. President & CEO Current
Oragenics, Inc. Board of Directors Current

Organization Position Status
Oragenics, Inc. Acting President and Chief Executive Officer Current
Evoraplus Chief Operating Officer, Chief Financial Officer Current
Oragenics, Inc. Board of Directors Current
Oragenics, Inc. Chief Financial Officer and Chief Operating Officer Former
Touche, Inc. Manager Former
California Inc Manager Former
Cottonwoodgroup.Com Associate Former
Drake University Law School Jd Former
Indiana University BA In Economics Former

Organization Position Status
Oragenics, Inc. President & CEO Current
Evoraplus Executive Vice President for Business Current
Oragenics, Inc. Board of Directors Current
Massachusetts, Inc. Chief Executive Officer Former
Professional Dental Technologies, Inc. General Manager Former
Therapeutics Incorporated General Manager Former
Professional Dental Technologies, Inc. Partner Former
Therapeutics Incorporated Partner Former
Massachusetts, Inc. Chairman of the Board of Directors Former
Ivigene Corporation Director Former
The Pennsylvania State University PhD In Physical Chemistry Former
Boston University PhD Degree Former
Boston University Bachelor of Science Degree In Chemistry Former
The Pennsylvania State University Bachelor of Science Degree In Chemistry Former

Organization Position Status
Oragenics, Inc. CEO & President Current
Oragenics, Inc. Board of Directors Current

Organization Position Status
Oragenics, Inc. Interim President and Chief Executive Officer and Director Current
Evoraplus President Current
Oragenics, Inc. Board of Directors Current
Dresdner Bank AG Head of the North American Corporate Finance Former
Dresdner Bank Head of the North American Corporate Finance Former
Columbia University J.D. Former
Columbia University B.A Former

Organization Position Status
Oragenics, Inc. President Current
Evoraplus Chief Scientific Officer Current
Oragenics, Inc. Founder Former
Oragenics, Inc. Chief Scientific Officer and Director Current
Venture Fund Management, LLC Board of Directors Current
Oragenics, Inc. Board of Directors Current
University of Florida Professor Former
Harvard Medical School PhD In Molecular Biology Former
Harvard School of Dental Medicine Dmd Degree (Cum Laude) Former
University of Chicago Undergraduate Former

Organization Position Status
Oragenics, Inc. Chief Financial Officer Current

Dr. Brian Mouatt served as the 5 th Chief Dental Officer for England and had previously served as Chief Dental Officer for Zambia. He is the past Chair of the International Dental Federation s (FDI) World Dental Development Health Promotion Committee where he is spear heading the drive to improve oral health in the developing world. This committee is responsible for the management of the World Dental Development Fund. As recent President of the Commonwealth Dental Association (CDA), he revitalized the association and instituted programs of distant learning and virtual meetings.

Organization Position Status
Oragenics, Inc. Th Chief Dental Officer for England Current

Organization Position Status
Oragenics, Inc. Chief Financial Officer Current
University of Hawaii Masters of Information Science Former
University of Florida Masters In Accounting Former

Organization Position Status
Bioflorida, Inc. Founder Current
Oragenics, Inc. Chairman and Director Current
Geneex, Inc. Chairman Current
Nabi Biopharmaceuticals Chairman Current
Redchip Companies, Inc. Director Current
Assureimmune LLC Board of Directors Current
Bioflorida, Inc. Board of Directors Current
Science, The Charles E. Schmidt College Board of Directors Current
Bioheart, Inc. Board of Directors Current
Nabi Biopharmaceuticals CEO Former
NABI President Former
Nabi Biopharmaceuticals President Former
NABI Chief Operating Officer Former
Nabi Biopharmaceuticals Chief Operating Officer Former
Arthur Anderson & Co. Intern Former
University of Chicago Research Fellow Former
Bioflorida, Inc. Chairman Former
Juvenile Diabetes Foundation Chairman Former
Geneex, Inc. Board of Directors Former
Juvenile Diabetes Foundation Director Former
Oragenics, Inc. Board of Directors Former
University of Chicago MBA Former
Kenyon College A.B. In Economics Former

Organization Position Status
Oragenics, Inc. Oragenics, Inc. Director Current
Proginet Corporation Audit Committee Chairman Current
Proginet Corporation Board of Directors Current
Oragenics, Inc. Board of Directors Current
Gentry Resources Ltd. Director Current
Midway Gold Corporation Board of Directors Current
Gentry Resources, Ltd. Former
KPMG International Former
Avon Products, Inc. Former
Cranstoun Former
University of Notre Dame Bba Former

Organization Position Status
Oragenics, Inc. Director for Its Center Dental Studies and Research Current

Organization Position Status
State University of New York at Buffalo Ub Distinguished Professor Current
Oragenics, Inc. Professor at the State University of New York at Buffalo Current
Immunity, Inc. Board of Directors Current
The Infection Board of Directors Current

Organization Position Status
Oragenics, Inc. Current
Piper Capital, LLC. Current
Bioflorida, Inc. President Former
Ernst & Young Senior Manager Former
Bryant University MBA In Management Former
Bryant University Master of Science In Taxation Former
Bryant University BS Accounting Former
American Institute of Certified Public Accountants Certificate In Financial Forensics Former

Dr. Per-Erik J. Saris, Ph.D . is a professor in food microbiology at the University of Helsinki in Finland. He is an expert in antibacterial peptides produced by bacteria. His team is part of the Centre of Excellence Microbial Resources appointed by the Academy of Finland. He was the first to amplify DNA directly from bacteria in 1990 and has since been active in different fields of molecular biology of bacteria including vaccine development, protein production, metabolic engineering and targeting of bacteria.

Organization Position Status
Oragenics, Inc. Professor Current

Organization Position Status
Oragenics, Inc. Board of Directors Current

Derek G. Hennecke. Mr. Hennecke, age 41, has served as a member of our board of directors since January 2008. Mr. Hennecke is an expert in drug development. He is a founder and CEO of Xcelience, a formulation and clinical manufacturing contract research company in Tampa, Florida. His management experiences over 25 years in the international biotechnology industry include: MDS Pharma Sciences, as Vice-president and General Manager for biopharmaceuticals, formulations, manufacturing, and pharmaceutics; DSM (contract manufacturing company) in active pharmaceutical ingredients, new business development (NBD) and manufacturing; and Biochemical Research Division of Boehringer Mannheim in NBD. His work included assignments in Europe, Egypt, Mexico, Canada, and USA. In these roles, he built the operations or businesses to introduce various drug products to Europe or the USA. During his career, Derek has worked in Germany and Canada for Roche s research activities. He earned a BS University of Alberta (Canada), and MBA, Erasmus University (Rotterdam, Netherlands).

Organization Position Status
Xcelience, LLC Chief Executive Officer & President Current
Oragenics, Inc. Board of Directors Current
Xcelience, LLC Board of Directors Current
Xcelience, LLC Founder Former
Roche Former
Erasmus University MBA Former
University of Alberta Bsc Former
Xcelience, LLC Member Former

Organization Position Status
Oragenics, Inc. Director Current
The Center for Professional Advancement Board of Directors Former

Organization Position Status
Oragenics, Inc. Board of Directors Current

Marc is Clinical Associate Professor of Medicine at NYU School of Medicine and Medical Director of Doctor Radio with NYU and Sirius Satellite Radio. Dr. Siegel is a Fox News Medical Contributor, a columnist for the Los Angeles Times, a member of the Board of Contributors at USA Today, a regular contributor to the NY Post, and a frequent contributor to the Washington Post, the Wall Street Journal, and Newsday. He is also the author of two non-fiction books, including False Alarm: the Truth about the Epidemic of Fear, a Discover Magazine top-twenty book of 2005.

Organization Position Status
Fear, Inc. Current
Oragenics, Inc. Board of Directors Current

Organization Position Status
Oragenics, Inc. Board of Directors Current
Louisiana State University Bsc In Management Former
Oragenics, Inc. Chairman Former

Executive News

  • Xcelience Expands Formulation Development and Quality Assurance

    Business Wire - 7/23/09 - View Story

  • Company Profile for Xcelience, LLC

    Business Wire - 7/10/09 - View Story

  • Oragenics Secures New Financing and Makes Changes to Its Board and Management

    TradingMarkets - 7/07/09 - View Story

  • BioFlorida Announces New Awards Ceremony at 12th Annual Conference November 4 - 6, 2009 at the JW Marriott Orlando, Grande Lakes

    Reuters - 7/01/09 - View Story

  • BioFlorida Announces New Awards Ceremony at 12th Annual Conference November 4 - 6, 2009 at the...

    Forbes.com - 7/01/09 - View Story

  • BioFlorida Announces New Awards Ceremony at 12th Annual Conference November 4 " 6, 2009 at the JW Marriott Orlando, Grande Lakes

    Business Wire - 7/01/09 - View Story

  • Oragenics Announces $5,000,000 in New Financing, and Changes in Its Board of Directors and...

    Forbes.com - 6/30/09 - View Story

  • Oragenics Announces $5,000,000 in New Financing, and Changes in Its Board of Directors and Management

    RBC Dain Raushcer - 6/30/09 - View Story